In Vitro Effects of Mercury on Platelet Aggregation, Thromboxane and Vascular Prostacyclin Production
- 1 January 1983
- book chapter
- Published by Springer Nature
- Vol. 6, 48-51
- https://doi.org/10.1007/978-3-642-69083-9_8
Abstract
Mercuric chloride [25–50 μg/ml platelet-rich plasma (PRP)] lowers the threshold concentration of arachidonic acid (AA) required for triggering rabbit platelet aggregation and causes a marked increase of thromboxane production. The metal, added as HgCl2, does not modify (50.μg/m1 PRP) or block (100 μg/ml PRP) the platelet aggregation wave induced by a normal aggregating dose of AA. Whether or not AA-induced platelet aggregation takes place, a large increase in thromboxane production is observed. Methyl mercury, assayed as reference drug, induces platelet aggregation and a significant increase of thromboxane levels. Finally, HgC12 and methyl mercury, in a concentration range of 0.125–0.5.μg/μl in the incubation liquid, induce an increased prostacyclin release from rat aortic tissue.Keywords
This publication has 4 references indexed in Scilit:
- “In vitro” activity of urokinase on platelet function and on ADP degradation by vascular tissueThrombosis Research, 1982
- Hemostasis, Thrombosis, and Thromboembolic Disorders: The Role of Arachidonic Acid Metabolites in Platelet-Vessel Wall InteractionsMedical Clinics of North America, 1981
- Platelet agglutination and deagglutination with a sulfhydryl inhibitor, methyl mercuric nitrate: Relationships to platelet ATPaseExperimental and Molecular Pathology, 1965
- Platelet aggregation: Part I Some effects of the adenosine phosphates, thrombin, and cocaine upon platelet adhesivenessJournal of Clinical Pathology, 1962